American Financial Group Inc increased its stake in Celgene Corp (CELG) by 100% based on its latest 2018Q3 regulatory filing with the SEC. American Financial Group Inc bought 25,000 shares as the company’s stock declined 22.96% with the market. The institutional investor held 50,000 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $4.47M, up from 25,000 at the end of the previous reported quarter. American Financial Group Inc who had been investing in Celgene Corp for a number of months, seems to be bullish on the $60.41B market cap company. The stock decreased 0.37% or $0.32 during the last trading session, reaching $86.27. About 13.19M shares traded or 35.56% up from the average. Celgene Corporation (NASDAQ:CELG) has declined 33.15% since January 20, 2018 and is downtrending. It has underperformed by 33.15% the S&P500. Some Historical CELG News: 04/05/2018 – CELGENE CEO MARK ALLES SPEAKS ON CELGENE CALL; 30/04/2018 – Merck: FDA Grants Priority Review to sBLA for Keytruda Combination; 25/04/2018 – European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and; 25/05/2018 – Oncolytics Biotech Collaborates With USC Using Pelareorep in Combination With Keytruda, Velcade and Dexamethasone to Treat Multiple Myeloma; 09/04/2018 – Merck’s Keytruda meets main goal in lung cancer trial; 23/05/2018 – Merck: Keytruda Has Shown Improved Survival Benefit in Advanced NSCLC in Five Phase 3 Trials; 16/05/2018 – Hagens Berman Reminds Investors in Celgene Corporation (CELG) of the May 29, 2018 Securities Class Action Lead Plaintiff Deadli; 07/05/2018 – CELG EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a; 16/03/2018 – GERMANY’S GBA SEES NO ADDED BENEFIT FOR NOVARTIS’S KISQALI; 29/05/2018 – Phase lll lMpower130 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to
Northeast Financial Consultants Inc decreased its stake in Metlife Inc Com (MET) by 39.39% based on its latest 2018Q3 regulatory filing with the SEC. Northeast Financial Consultants Inc sold 32,841 shares as the company’s stock declined 13.12% with the market. The institutional investor held 50,543 shares of the finance company at the end of 2018Q3, valued at $2.36 million, down from 83,384 at the end of the previous reported quarter. Northeast Financial Consultants Inc who had been investing in Metlife Inc Com for a number of months, seems to be less bullish one the $44.71 billion market cap company. The stock increased 0.58% or $0.26 during the last trading session, reaching $45.31. About 6.46M shares traded. MetLife, Inc. (NYSE:MET) has declined 26.13% since January 20, 2018 and is downtrending. It has underperformed by 26.13% the S&P500. Some Historical MET News: 02/04/2018 – MetLife Investment Management Reaches $2.9 Billion of Global Agricultural Mortgage Production for 2017; 30/03/2018 – METLIFE – STRATEGIC PARTNERSHIP TO OFFER INSURANCE SOLUTIONS TO TRAVELLERS THROUGH TENCENT’S WESURE ONLINE INSURANCE PLATFORM; 16/05/2018 – MetLife Launches PlanSmart(R) Fincl Wellness; 01/05/2018 – Metlife Will ‘Continue to Grow Organically,’ Says CIO (Video); 02/05/2018 – MetLife 1Q Adj EPS $1.36; 26/04/2018 – MetLife CEO Issues Another Mea Culpa for Recent String of Errors; 01/05/2018 – MetLife Announces Senior Leadership Changes; 23/03/2018 – Sanford Heisler Sharp Wins Conditional Certification In $50 Million Nationwide Class Action Lawsuit Against MetLife For Overtim; 29/03/2018 – April 6th Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against MetLife, Inc. (MET); 23/03/2018 – Sanford Heisler Sharp Wins Conditional Certification In $50 Million Nationwide Class Action Lawsuit Against MetLife For Overtime Pay Violations
Analysts await MetLife, Inc. (NYSE:MET) to report earnings on February, 12. They expect $1.31 earnings per share, up 18.02% or $0.20 from last year’s $1.11 per share. MET’s profit will be $1.29B for 8.65 P/E if the $1.31 EPS becomes a reality. After $1.38 actual earnings per share reported by MetLife, Inc. for the previous quarter, Wall Street now forecasts -5.07% negative EPS growth.
Northeast Financial Consultants Inc, which manages about $2.86 billion and $364.23M US Long portfolio, upped its stake in Pepsico Inc (NYSE:PEP) by 5,298 shares to 16,531 shares, valued at $1.85M in 2018Q3, according to the filing. It also increased its holding in Dowdupont Inc by 5,310 shares in the quarter, for a total of 12,322 shares, and has risen its stake in Intl Business Machines (NYSE:IBM).
Investors sentiment decreased to 0.86 in 2018 Q3. Its down 0.03, from 0.89 in 2018Q2. It worsened, as 47 investors sold MET shares while 324 reduced holdings. 81 funds opened positions while 237 raised stakes. 739.18 million shares or 1.70% less from 751.98 million shares in 2018Q2 were reported. Private Advisor Grp Incorporated Limited Liability Corp holds 0.04% or 39,455 shares. Klingenstein Fields & Ltd Com accumulated 364,996 shares. Tennessee-based Td Mgmt Limited Liability Corporation has invested 0.01% in MetLife, Inc. (NYSE:MET). Hall Laurie J Trustee stated it has 0.01% of its portfolio in MetLife, Inc. (NYSE:MET). 116,839 were accumulated by Oppenheimer & Inc. 9,829 were reported by Univest Of Pennsylvania. Quantitative Investment Management Llc accumulated 0.12% or 70,100 shares. Rmb Management Ltd Limited Liability Company holds 0.05% or 41,768 shares. Korea Inv reported 0.09% stake. Nelson Van Denburg & Campbell Wealth Gp Ltd Co invested in 2,778 shares. Lombard Odier Asset Mngmt (Switzerland) Sa owns 9,519 shares or 0.04% of their US portfolio. San Francisco Sentry Inv Group (Ca), California-based fund reported 1,170 shares. Cibc Asset Inc reported 96,755 shares stake. First National Trust Com holds 0.33% or 69,114 shares. Perkins Coie stated it has 44,861 shares.
More news for MetLife, Inc. (NYSE:MET) were recently published by: Businesswire.com, which released: “MetLife Names Darla Finchum Head of MetLife Auto & Home® – Business Wire” on January 16, 2019. 247Wallst.com‘s article titled: “Merrill Lynch Calls for Big Upside in Life Insurance Sector Leaders – 24/7 Wall St.” and published on January 16, 2019 is yet another important article.
Among 19 analysts covering MetLife (NYSE:MET), 10 have Buy rating, 1 Sell and 8 Hold. Therefore 53% are positive. MetLife had 67 analyst reports since July 31, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Friday, October 7 by Credit Suisse. Argus Research maintained it with “Buy” rating and $55 target in Wednesday, August 9 report. Barclays Capital maintained the stock with “Overweight” rating in Friday, August 11 report. The stock of MetLife, Inc. (NYSE:MET) earned “Hold” rating by Bank of America on Monday, March 26. The company was downgraded on Tuesday, January 5 by Citigroup. The firm earned “Buy” rating on Friday, August 4 by RBC Capital Markets. The rating was maintained by Keefe Bruyette & Woods on Thursday, December 21 with “Buy”. The stock of MetLife, Inc. (NYSE:MET) earned “Outperform” rating by RBC Capital Markets on Monday, December 17. On Monday, July 16 the stock rating was maintained by FBR Capital with “Neutral”. The firm has “Buy” rating given on Monday, July 10 by Wells Fargo.
Investors sentiment increased to 0.93 in Q3 2018. Its up 0.22, from 0.71 in 2018Q2. It is positive, as 58 investors sold CELG shares while 418 reduced holdings. 113 funds opened positions while 332 raised stakes. 468.90 million shares or 1.67% less from 476.86 million shares in 2018Q2 were reported. Mitsubishi Ufj Tru Bk stated it has 774,880 shares. Twin Mgmt owns 0.09% invested in Celgene Corporation (NASDAQ:CELG) for 22,330 shares. Chevy Chase Holdings Inc has invested 0.24% of its portfolio in Celgene Corporation (NASDAQ:CELG). Rosenblum Silverman Sutton S F Ca owns 66,181 shares for 1.96% of their portfolio. 1St Source Retail Bank holds 5,997 shares or 0.04% of its portfolio. 6,900 were reported by Smith Asset Mgmt Gru L P. British Columbia Management Corp invested in 0.24% or 250,092 shares. Ameritas Invest reported 0.13% of its portfolio in Celgene Corporation (NASDAQ:CELG). Ferguson Wellman Capital Management invested in 0.01% or 3,617 shares. Atwood And Palmer, a Missouri-based fund reported 86,276 shares. Renaissance holds 1.55M shares. Hanson Mcclain has invested 0% in Celgene Corporation (NASDAQ:CELG). Hanson & Doremus Inv Management invested 0.02% of its portfolio in Celgene Corporation (NASDAQ:CELG). 575,537 were accumulated by Bristol John W & New York. Perigon Wealth Mgmt Ltd Liability Corp accumulated 32,313 shares.
More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Seekingalpha.com which released: “Celgene and Alliqua BioMedical among healthcare gainers; Bristol-Myers Squibb and Prana Biotechnology among losers – Seeking Alpha” on January 03, 2019, also Fool.com with their article: “Why Celgene, Agenus, and Incyte Jumped Today – The Motley Fool” published on January 03, 2019, Nasdaq.com published: “The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie – Nasdaq” on January 07, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Nasdaq.com and their article: “IVV’s Holdings Imply 25% Gain Potential – Nasdaq” published on December 31, 2018 as well as Seekingalpha.com‘s news article titled: “Onconova readies late-stage study jof rigosertib combo in myelodysplastic syndromes – Seeking Alpha” with publication date: January 02, 2019.
Among 35 analysts covering Celgene Corporation (NASDAQ:CELG), 23 have Buy rating, 0 Sell and 12 Hold. Therefore 66% are positive. Celgene Corporation had 160 analyst reports since July 21, 2015 according to SRatingsIntel. William Blair maintained the stock with “Buy” rating in Wednesday, February 28 report. Canaccord Genuity maintained the shares of CELG in report on Friday, October 27 with “Buy” rating. The rating was maintained by Credit Suisse with “Buy” on Thursday, July 6. Wells Fargo downgraded the stock to “Hold” rating in Thursday, October 26 report. Jefferies maintained Celgene Corporation (NASDAQ:CELG) on Sunday, October 15 with “Buy” rating. Cantor Fitzgerald maintained the stock with “Buy” rating in Thursday, July 6 report. As per Tuesday, January 23, the company rating was maintained by Canaccord Genuity. The rating was upgraded by Atlantic Securities on Friday, December 8 to “Overweight”. The firm has “Hold” rating by Argus Research given on Friday, May 5. The stock of Celgene Corporation (NASDAQ:CELG) earned “Overweight” rating by JP Morgan on Wednesday, March 21.
American Financial Group Inc, which manages about $1.01 billion US Long portfolio, decreased its stake in Signet Jewelers Limited (NYSE:SIG) by 40,000 shares to 10,000 shares, valued at $660,000 in 2018Q3, according to the filing.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.